Infinity Pharmaceuticals (INFI) stock surged 21.52% to$4.880 in the morning today. Given the past, we will look into many developments that could have caused INFI to advance or regress. The stock rose 6.76 percent in the last five days and 7.96% over the past month. During the prior quarter, the stock climbed by 243.48%.
Latest Publications
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
February 11, 2021, Infinity Pharmaceuticals (INFI) plans to outline its long-term investment thesis at the BIO CEO & Investor Conference. taking place February 16-18. Presentations details are below:
BIO CEO & Investor Conference Presentation Details:
Presentation: Available on-demand starting February 16 at 10 am EST
The link for the presentation will be available at www.infi.com.
Before this News on the same day, Infinity Pharmaceuticals (INFI) revealed results from the Phase 2 MARIO-275 study, which was a randomized, placebo-controlled trial conducted to test the efficacy of eganelisib with nivolumab in platinum-resistant, metastatic breast cancer
Its primary goal was to address the need for improved treatments for the second line (2L) advanced urothelial cancer patients. Its secondary aim was to investigate the potential for improving treatments for early stage (EC) urothelial cancer patients.
Summary:
Biotech companies create medicines and medical treatments using innovative science so that they can put big profits in the pockets of investors with a keen eye for future health trends. Investors interested in the biotechnology sector understand it is often a long wait for premiums to grow, as companies wait on FDA approvals and feedback.